Functional polymorphism in the MicroRNA-367 binding site as a prognostic factor for colonic cancer

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 513-520

  Chae, Yee Soo ^a   Kim, Jong Gwang ^a,b   Kang, Byung Woog ^a   Lee, Soo Jung ^a   Lee, Yoo Jin ^a   Park, Jun Seok ^a   Choi, Gyu Seog ^a,b   Lee, Won Kee ^a   Jeon, Hyo Sung ^b  

^a Department of Oncology/Hematology ^*  (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

Colonic cancer; MicroRNA; MicroRNAbinding site; Polymorphism; Prognosis; Rs1044129

Indexed keywords

CAPECITABINE; DNA; DOXIFLURIDINE; FLUOROURACIL; FOLINIC ACID; MICRORNA; MICRORNA 367; OXALIPLATIN; RYANODINE RECEPTOR 3; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BINDING SITE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE SPECIFIC SURVIVAL; DNA EXTRACTION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 84875910927     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, Park JY, Jeon SW, Lee IT, Choi GS and Jun SH: Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 14: 62-66, 2008.
2. Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK and Lenz HJ: Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res 14: 7884-7895, 2008.
3. Hebbar M, Adenis A, Revillion F, Duhamel A, Romano O, Truant S, Libersa C, Giraud C, Triboulet JP, Pruvot FR and Peyrat JP: E-selectin gene S128R polymorphism is associated with poor prognosis in patients with stage II or III colorectal cancer. Eur J Cancer 45: 1871-1876, 2009.
4. Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y and Sugimachi K: Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg 87: 353-357, 2000.
5. Uthoff SM, Duchrow M, Schmidt MH, Broll R, Bruch HP, Strik MW and Galandiuk S: VEGF isoforms and mutations in human colorectal cancer. Int J Cancer 101: 32-36, 2002.
6. Chae YS, Kim JG, Sohn SK, Cho YY, Ahn BM, Moon JH, Jeon SW, Park JY, Lee IT, Choi GS and Jun SH: Association of vascular endothelial growth factor gene polymorphisms with susceptibility and clinicopathologic characteristics of colorectal cancer. J Korean Med Sci 23: 421-427, 2008.
7. Hofmann G, Langsenlehner U, Renner W, Langsenlehner T, Yazdani-Biuki B, Clar H, Gerger A, Wehrschuetz M, Samonigg H and Krippl P: Common single nucleotide polymorphisms in the vascular endothelial growth factor gene and colorectal cancer risk. J Cancer Res Clin Oncol 134: 591-595, 2008.
8. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
9. Chang SS, Jiang WW, Smith I, Poeta LM, Begum S, Glazer C, Shan S, Westra W, Sidransky D and Califano JA: MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer 123: 2791-2797, 2008.
10. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R and Vyzula R: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72: 397-402, 2007.
11. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM and Harris CC: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. Jama 299: 425-436, 2008.
12. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M and Ju J: Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics 3: 317-324, 2006.
13. Meister G and Tuschl T: Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343-349, 2004.
14. Song F, Zheng H, Liu B, Wei S, Dai H, Zhang L, Calin GA, Hao X, Wei Q, Zhang W and Chen K: An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset. Clin Cancer Res 15: 6292-6300, 2009.
15. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ and Weidhaas JB: A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res 68: 8535-8540, 2008.
16. Hamilton SR AL Ed: WHO Classification of Tumours: Pathology and Genetics of Tumours of Digestive System. WHO, Geneva, Switzerland 2000.
17. Greene FL: TNM staging for malignancies of the digestive tract: 2003 changes and beyond. Semin Surg Oncol 21: 23-29, 2003.
18. Hu Y, Liu CM, Qi L, He TZ, Shi-Guo L, Hao CJ, Cui Y, Zhang N, Xia HF and Ma X: Two common SNPs in pri-miR-125a alter the mature miRNA expression and associate with recurrent pregnancy loss in a Han-Chinese population. RNA Biol 8: 861-872.
19. Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, Slack F, Zhang Y, Paranjape T and Zhu Y: microRNA miR-196a-2 and breast cancer: A genetic and epigenetic association study and functional analysis. Cancer Res 69: 5970-5977, 2009.
20. Tian T, Shu Y, Chen J, Hu Z, Xu L, Jin G, Liang J, Liu P, Zhou X, Miao R, Ma H, Chen Y and Shen H: A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev 18: 1183-1187, 2009.
21. Zhang L, Liu Y, Song F, Zheng H, Hu L, Lu H, Liu P, Hao X, Zhang W and Chen K: Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci USA 108: 13653-13658.
22. Xiong F, Wu C, Chang J, Yu D, Xu B, Yuan P, Zhai K, Xu J, Tan W and Lin D: Genetic variation in an miRNA-1827 binding site in MYCL1 alters susceptibility to small-cell lung cancer. Cancer Res 71: 5175-5181.
23. Wynendaele J, Bohnke A, Leucci E, Nielsen SJ, Lambertz I, Hammer S, Sbrzesny N, Kubitza D, Wolf A, Gradhand E, Balschun K, Braicu I, Sehouli J, Darb-Esfahani S, Denkert C, Thomssen C, Hauptmann S, Lund A, Marine JC and Bartel F: An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res 70: 9641-9649.
24. Abdollahi MR, Lewis RM, Gaunt TR, Cumming DV, Rodriguez S, Rose-Zerilli M, Collins AR, Syddall HE, Howell WM, Cooper C, Godfrey KM, Cameron IT and Day IN: Quantitated transcript haplotypes (QTH) of AGTR1, reduced abundance of mRNA haplotypes containing 1166C (rs5186:A>C), and relevance to metabolic syndrome traits. Hum Mutat 28: 365-373, 2007.
25. Verma V, Carter C, Keable S, Bennett D and Thorn P: Identification and function of type-2 and type-3 ryanodine receptors in gut epithelial cells. Biochem J 319(Pt 2): 449-454, 1996.
26. Abdul M, Ramlal S and Hoosein N: Ryanodine receptor expression correlates with tumor grade in breast cancer. Pathol Oncol Res 14: 157-160, 2008.
27. Giannini G, Clementi E, Ceci R, Marziali G, and Sorrentino V: Expression of a ryanodine receptor-Ca2+ channel that is regulated by TGF-beta. Science 257: 91-94, 1992.
28. Costa FF, Bischof JM, Vanin EF, Lulla RR, Wang M, Sredni ST, Rajaram V, Bonaldo Mde F, Wang D, Goldman S, Tomita T and Soares MB: Identification of microRNAs as potential prognostic markers in ependymoma. PLoS One 6: e25114, 2011.
29. Gill S and Sargent D: End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? Oncologist 11: 624-629, 2006.
30. de Gramont A, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A and Sargent D: Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol 28: 460-465, 2010.
31. Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA and Pai RK: Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: An adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol 25: 1128-1139, 2012.
32. Soreide K, Janssen EA, Soiland H, Korner H and Baak JP: Microsatellite instability in colorectal cancer. Br J Surg 93: 395-406, 2006.